Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StrataPATH
NCT05097599Phase 2Terminated
- Sponsor
- Strata Oncology
- Start
- Apr 2022
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of lorlatinib, encorafenib, binimetinib, talazoparib, sacituzumab govitecan in solid tumor, sponsored by Strata Oncology. Started Apr 2022; status: terminated.
02
Drugs
lorlatinibencorafenibbinimetinibtalazoparibsacituzumab govitecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05097599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097599.